Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565941 · ClinicalTrials.gov registry record · Phase 3
Heart And Lung Failure - Pediatric INsulin Titration Trial
A Phase 3 study of Heart Failure and Respiratory Failure, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 713
- Enrollment target
- 20
- Study locations
NCT01565941: Completed Phase 3 study of Heart Failure and Respiratory Failure, sponsored by Boston Children's Hospital.
NCT01565941 is a Phase 3 study of Heart Failure and Respiratory Failure that has completed, run by Boston Children's Hospital. The registered enrollment target is 713 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01565941, a Phase 3 study of Heart Failure and Respiratory Failure, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 713 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical patients but has since come under intense scrutiny due to conflicting results in recent adult trials. One pediatric RCT has been published to date that demonstrated survival benefit but was complicated by an unacceptably high rate of severe hypoglycemia. The Heart And Lung Failure - Pediatric INsulin Titration (HALF-PINT) trial is a multi-center, randomized clinical treatment trial comparing two ranges of glucose control in hyperglycemic critically ill children with heart and/or lung failure. Both target ranges of glucose control fall within the range of "usual care" for critically ill children managed in pediatric intensive care units. The purpose of the study is to determine the comparative effectiveness of tight glycemic control to a target range of 80-110 mg/dL (TGC-1, 4.4-6.1 mmol/L) vs. a target range of 150-180 mg/dL (TGC-2, 8.3-10.0 mmol/L) on hospital mortality and intensive care unit (ICU) length of stay (LOS) in hyperglycemic critically ill children with cardiovascular and/or respiratory failure. This will be accomplished using an explicit insulin titration algorithm and continuous glucose monitoring to safely achieve these glucose targets. Both groups will receive identical standardized intravenous glucose at an age-appropriate rate in order to provide basal calories and mitigate hypoglycemia. Insulin infusions will be titrated with an explicit algorithm combined with continuous glucose monitoring using a protocol that has been safely implemented in 490 critically ill infants and children.
Primary Outcome
28-day hospital mortality-adjusted ICU length of stay.
Conditions Studied
Interventions
- DRUG Insulin
Study Locations (20)
California
- Miller Children's Hospital Long Beach - Long Beach
- Children's Hospital of Los Angelos - Los Angeles
- Mattel Children's Hospital - Los Angeles
- Children's Hospital & Research Center of Oakland - Oakland
- Children's Hospital of Orange County - Orange
- UCSF Benioff Children's Hospital - San Francisco
Illinois
- Ann & Robert H. Lurie Children's Hospital pf Chicago - Chicago
- University of Chicago Comer Children's Hospital - Chicago
Maryland
- University of Maryland Medical Center - Baltimore
- Johns Hopkins Hospital - Baltimore
Colorado
- Children's Hospital Colorado - Aurora
Connecticut
- Yale-New Haven Children's Hospital - New Haven
Delaware
- Nemours/A.I DuPont Hospital for Children - Wilmington
Georgia
- Children's Healthcare of Atlanta - Atlanta
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 713 participants |
| Start Date | 2012-04 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
What the finished NCT01565941 record still lists
NCT01565941 is an interventional study that assigns participants to a tested intervention. The registered 713 participants enrollment target is mid-sized for trials with a published cap, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Insulin is the first listed.
NCT01565941 names 20 study sites across 13 states, led by California, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT01565941 about?
NCT01565941 is a clinical study titled "Heart And Lung Failure - Pediatric INsulin Titration Trial". Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical pa...
What is the current status of trial NCT01565941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 713 participants. The study started on 2012-04. Estimated completion is 2018-02.
What conditions does trial NCT01565941 study?
This clinical trial studies the following conditions: Heart Failure, Respiratory Failure.
What interventions are being tested in trial NCT01565941?
The interventions under investigation include: Insulin (DRUG).
Who is sponsoring clinical trial NCT01565941?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01565941 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01565941's enrollment target sits among peer trials
713 84th of 397 higher than 314 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia